Most biotech leaders understand that launch preparation, building the plan, begins well before expected approval.…

Strategic planning within a company must be interconnected, with a clear hierarchy that aligns every effort with the…

A well-informed asset strategy is an essential component of developing a novel therapy to meet critical patient needs.

The biggest risk for pre-commercial companies is being singularly focused on a lean development program without…

Some people need to “think out loud.” Others are eager to get right to the point. Toss in challenging schedules and…

The first edition of "Connecting the Dots" was published on September 29, 2017. Since Sue Nemetz penned that inaugural…

As readers of The NemetzGroup newsletter know, we often use this space to consider progress in biopharma, new…

Biopharma companies need to balance many critical priorities, especially those that are pre-commercial.

What is the correct metaphor for today’s biopharma job market? A roller-coaster? A crater? A dark cloud? A correction?……

As summer winds down and vacations (sadly) come to an end, it’s a natural time to shift focus toward the close of the…